Boehringer Ingelheim's hep C candidate gets EMA fast-track assessment
This article was originally published in Scrip
Executive Summary
The EMA has granted an accelerated assessment to Boehringer Ingelheim's approval application for its second-generation hepatitis C protease inhibitor faldaprevir for use in combination with pegylated interferon and ribavirin.